Arguments in Chemical Abortion Case Could Create Friction With Pro-Lifers

CompassCare CEO Jim Harden voices concerns over the forthcoming arguments in the FDA's case.

RALEIGH, N.C., May 19, 2023 /PRNewswire-PRWeb/ -- On Wednesday, May 17, the U.S. 5th Circuit Court of Appeals is scheduled to hear arguments regarding the FDA's illegal approval and subsequent deregulation of the lethal chemical abortion drug, Mifepristone. However, pro-life strategists are concerned the case could result from a response by the pro-abortion community, such as took place in March when arguments were heard at the 5th Circuit U.S. District Court. This was when a pro-life medical network in New York, CompassCare, was vandalized a second time. CompassCare CEO, Rev. Jim Harden, notified the FBI of concerns that the case would reignite a stir from the pro-abortion community.

Chemical abortion now represents over half of all abortion in the U.S. Overturning the FDA's Clinton-era, fast-track approval of the drug would cut abortion in half overnight. This case would have a larger impact on the abortion landscape than even reversing Roe?a decision that sparked the prairie fire of violent pro-abortion recruitment and direct action against peaceful pro-life entities like CompassCare.

Rev. Harden notes, "Civil societies never see death as a solution to debates. All people are made in the image of God and ought to be treated with dignity commensurate with that truth. Societies that forget God fall headlong into self-destruction. Abortion and the rampant violence swirling among us should be taken as a fog horn warning the ship of state to avoid the shoals of godlessness and the resulting wickedness that will surely sink us."

Media Contact

Gerald McGlothlin, Special Guests, 919-437-0001, [email protected]

SOURCE CompassCare